Selective Estrogen Receptor Modulators

"Selective Estrogen Receptor Modulators" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A structurally diverse group of compounds distinguished from ESTROGENS by their ability to bind and activate ESTROGEN RECEPTORS but act as either an agonist or antagonist depending on the tissue type and hormonal milieu. They are classified as either first generation because they demonstrate estrogen agonist properties in the ENDOMETRIUM or second generation based on their patterns of tissue specificity. (Horm Res 1997;48:155-63)

Descriptor ID	D020845
MeSH Number(s)	D06.347.360.827 D27.505.696.399.450.360.827
Concept/Terms	Selective Estrogen Receptor Modulators Selective Estrogen Receptor Modulators SERMs Estrogen Receptor Modulators, Selective Selective Estrogen Receptor Modulator SERM Estrogen Receptor Modulator, Selective

Below are MeSH descriptors whose meaning is more general than "Selective Estrogen Receptor Modulators".

Chemicals and Drugs [D]
Hormones, Hormone Substitutes, and Hormone Antagonists [D06]
Hormone Antagonists [D06.347]
Estrogen Receptor Modulators [D06.347.360]
Selective Estrogen Receptor Modulators [D06.347.360.827]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Physiological Effects of Drugs [D27.505.696]
Hormones, Hormone Substitutes, and Hormone Antagonists [D27.505.696.399]
Hormone Antagonists [D27.505.696.399.450]
Estrogen Receptor Modulators [D27.505.696.399.450.360]
Selective Estrogen Receptor Modulators [D27.505.696.399.450.360.827]

Below are MeSH descriptors whose meaning is related to "Selective Estrogen Receptor Modulators".

Below are MeSH descriptors whose meaning is more specific than "Selective Estrogen Receptor Modulators".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Selective Estrogen Receptor Modulators" by people in this website by year, and whether "Selective Estrogen Receptor Modulators" was a major or minor topic of these publications.

Bar chart showing 18 publications over 12 distinct years, with a maximum of 3 publications in 2007 and 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	2	0	2
2003	1	1	2
2007	2	1	3
2008	0	1	1
2011	1	0	1
2012	0	1	1
2013	1	0	1
2014	2	1	3
2016	1	0	1
2018	1	0	1
2020	1	0	1
2023	1	0	1

Below are the most recent publications written about "Selective Estrogen Receptor Modulators" by people in Profiles.

Abdulkareem AO, Tiwari P, Lone ZR, Iqbal H, Gupta S, Jha RK, Chanda D, Jagavelu K, Hanif K. Ormeloxifene, a selective estrogen receptor modulator, protects against pulmonary hypertension. Eur J Pharmacol. 2023 Mar 15; 943:175558.

View in: PubMed
Guo S, Zhang C, Mottamal M, Hossain A, Liu J, Wang G. GLL398, an oral selective estrogen receptor degrader (SERD), blocks tumor growth in xenograft breast cancer models. Breast Cancer Res Treat. 2020 Apr; 180(2):359-368.

View in: PubMed
Hernandez G, Zhao L, Franke AA, Chen YL, Mack WJ, Brinton RD, Schneider LS. Pharmacokinetics and safety profile of single-dose administration of an estrogen receptor ?-selective phytoestrogenic (phytoSERM) formulation in perimenopausal and postmenopausal women. Menopause. 2018 02; 25(2):191-196.

View in: PubMed
Liu J, Zheng S, Akerstrom VL, Yuan C, Ma Y, Zhong Q, Zhang C, Zhang Q, Guo S, Ma P, Skripnikova EV, Bratton MR, Pannuti A, Miele L, Wiese TE, Wang G. Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD). J Med Chem. 2016 09 08; 59(17):8134-40.

View in: PubMed
Green JE, Cooperwood JS, Taka E, Soliman KF, Goodman CB, Reams RR. Comparative proteomic analysis reveals growth inhibition by 3-N-alkyloxyestradiol derivative (SERM) in prostate cancer cells. Cancer Genomics Proteomics. 2014 Jul-Aug; 11(4):195-200.

View in: PubMed
Karki P, Webb A, Zerguine A, Choi J, Son DS, Lee E. Mechanism of raloxifene-induced upregulation of glutamate transporters in rat primary astrocytes. Glia. 2014 Aug; 62(8):1270-83.

View in: PubMed
Karki P, Smith K, Johnson J, Lee E. Astrocyte-derived growth factors and estrogen neuroprotection: role of transforming growth factor-a in estrogen-induced upregulation of glutamate transporters in astrocytes. Mol Cell Endocrinol. 2014 May 25; 389(1-2):58-64.

View in: PubMed
Perry R, Thompson CA, Earnhardt JN, Wright DJ, Bailey S, Komm B, Cukierski MA. Renal tumors in male rats following long-term administration of bazedoxifene, a tissue-selective estrogen receptor modulator. Toxicol Pathol. 2013; 41(7):1001-10.

View in: PubMed
Lee E, Sidoryk-Wegrzynowicz M, Yin Z, Webb A, Son DS, Aschner M. Transforming growth factor-a mediates estrogen-induced upregulation of glutamate transporter GLT-1 in rat primary astrocytes. Glia. 2012 Jul; 60(7):1024-36.

View in: PubMed
Grigsby JG, Parvathaneni K, Almanza MA, Botello AM, Mondragon AA, Allen DM, Tsin AT. Effects of tamoxifen versus raloxifene on retinal capillary endothelial cell proliferation. J Ocul Pharmacol Ther. 2011 Jun; 27(3):225-33.

View in: PubMed

People

Explore

Similar Concepts

Top Journals